Merkin Prize in Biomedical Technology awarded to F. William Studier for development of widely used protein- and RNA-production platform

USA - English

News provided by

May 14, 2024, 14:06 ET

The $400,000 award recognizes the far-reaching medical impacts of Studier's development, in the 1980s, of an efficient and scalable technology to produce mass amounts of RNA and proteins in laboratories that is widely used today all over the world

CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- F. William Studier of Brookhaven National Laboratory has won the second annual Richard N. Merkin Prize in Biomedical Technology for his development of an efficient, scalable method of producing RNA and proteins in the laboratory. His T7 expression technology can be used to make large quantities of nearly any RNA or protein and has been for decades, and continues to be, a mainstay of biomedical research and pharmaceutical production. The approach has been used to produce numerous therapeutics, diagnostics, and vaccines — including the COVID-19 mRNA vaccines credited with extending millions of lives in recent years.

"F. William Studier's brilliant work on the T7 system transformed biomedicine, saving millions of lives globally and improving the chances for further research that will change healthcare delivery," said Dr. Richard Merkin, CEO and Founder of Heritage Provider Network, one of the country's largest physician-owned integrated health care systems. "His work exemplifies why I created this prize initiative that honors and showcases amazing innovators like Bill. I'm honored to be celebrating his remarkable achievements."

The Merkin Prize, which recognizes novel technologies that have improved human health, carries a $400,000 cash award and is administered by the Broad Institute of MIT and Harvard, one of the world's leading biomedical research institutes. All nominations for the 2024 Merkin Prize were evaluated by a selection committee, composed of nine scientific leaders from academia and industry in the US and Europe. Studier will be honored in a prize ceremony held on September 17, 2024.

"The T7 system has been influential in biomedicine and has had important clinical implications for many years, but Bill Studier's contribution to the field has really not been as celebrated as it ought to be," said Harold Varmus, chair of the Merkin Prize selection committee. Varmus is also the Lewis Thomas University Professor at Weill Cornell Medicine, a senior associate at the New York Genome Center, and a recipient of the Nobel Prize in Physiology or Medicine for his work on the origins of cancer.

"Bill Studier's development of T7 phage RNA polymerase for use in preparing RNA templates for multiple uses in research labs worldwide has been a truly revolutionary technical advance for the entire field of molecular biology," says Joan Steitz, the Sterling Professor of Molecular Biophysics and Biochemistry at Yale University.

"Today, virtually every protein you want to produce in bacteria is made with a T7 system," says Venki Ramakrishnan of the MRC Laboratory of Molecular Biology in Cambridge, England, and a winner of the 2009 Nobel Prize in Chemistry. "There's not a single molecular biology or biochemistry lab I know that doesn't use T7."

Driven by basic biology

Studier grew up in Iowa and became fascinated with biophysics while an undergraduate at Yale University. Then, during graduate school at the California Institute of Technology in the early 1960s, he was introduced to bacteriophage T7, a virus that infects Escherichia coli bacteria. He wondered how T7 could so effectively and quickly take over E. coli, rapidly turning the bacterial cells into factories to produce more T7. That question launched a career focused on the basic biology of T7.

"I've always been interested in solving problems," Studier told Brookhaven National Laboratory in a 2011 profile. "The motivation for my research is not commercial application. My interest is in basic research."

When he launched his own lab at Brookhaven National Laboratory in 1964, Studier focused on sequencing the genes of the T7 bacteriophage and understanding the function of each of its corresponding proteins during infection of E. coli. By 1984, he and Brookhaven colleague John Dunn successfully identified and cloned the protein within T7 that was responsible for rapidly copying T7 DNA into many corresponding strands of RNA — a critical step in the bacteriophage's ability to infect E. coli.

Studier realized that the protein, called the T7 RNA polymerase, might be able to quickly and efficiently produce RNA from not only T7 DNA, but also from the genes of any organism. If a gene was tagged with a special DNA sequence, known as the T7 promoter, then the T7 RNA polymerase would latch on and begin copying it. In 1986, Studier described this system in the Journal of Molecular Biology.

"His work really illustrates that sometimes a remarkable technology can emerge not only from people trying to build technologies but from someone who is trying to use basic science to understand a fascinating biological phenomenon," says Varmus.

Speeding science

Before Studier's development of the T7 system, scientists who wanted to produce RNA or proteins generally inserted the genes into the natural E. coli genome and let the E. coli polymerase produce the corresponding RNA at the same time as the bacteria produced its own RNA and proteins. But the E. coli machinery was relatively slow, and scientists often ran into problems with the bacteria turning off their DNA-reading programs. T7 polymerase overcame both these problems: it was far faster and E. coli had no built-in way to shut it off.

Within a few years, biologists had rapidly switched from their older methods to the T7 system for producing both RNA and proteins. When proteins are the desired end result, the E. coli molecular machinery for translating mRNA into proteins is used after the T7 system makes the RNA.

Studier continued studying the T7 polymerase and promoter, fine-tuning the system for years, and publishing new improved versions as recently as 2018.

As of 2020, the T7 technology had been cited in more than 220,000 published studies, with 12,000 new studies using the technology published each year. There are more than 100 different versions of the T7 technology available commercially and 12 patents in Studier's name related to the system.

Making medicine

The T7 technology has also had immediate impacts in industry, with more than 900 biotech and pharmaceutical companies licensing it to produce therapeutics and vaccines.

In 2020, scientists used the T7 platform to produce enough mRNA for COVID-19 vaccines to vaccinate millions of people in the U.S. and around the world. With the T7 promoter placed next to the gene for the COVID-19 spike protein, the T7 polymerase could generate many kilograms of mRNA — the active molecule in the vaccines — at a time.

"I think it's an incredible testament to this technology that, decades after its development, it's still the go-to method for RNA and protein production," says John Shanklin, a distinguished biochemist and Chair of Biology at Brookhaven National Laboratory, who considered Studier a mentor for many years.

Those who know Studier say the Merkin Prize is well-deserved; Studier changed the course of biomedicine while working quietly on basic science questions that interested him.

"Almost no one has heard of Bill Studier because he is a quiet, modest guy who had a small lab," says Ramakrishnan, who worked with Studier at Brookhaven in the 1980s. "But he is an absolutely fantastic role model of what a scientist should be like."

"He has flown under the radar and hasn't been recognized for his accomplishments very much," agrees Shanklin. "This is a well-deserved honor."

Studier was also committed to guaranteeing access to his technology. When Brookhaven was in the process of licensing and commercializing the T7 system shortly after its development, Studier ensured that it remained free for academic labs while charging commercial licensing fees to companies.

Studier is a Senior Biophysicist Emeritus at Brookhaven National Laboratory and has been elected to the American Association for the Advancement of Science, the American Academy of Arts and Sciences, and the National Academy of Inventors. He retired from the lab in 2015 and lives with his wife in California, where he still plays tennis at age 88.

Nominations for the 2025 Merkin Prize open on August 5, 2024. Visit merkinprize.org for more information.

About the Merkin Family Foundation
The Merkin Family Foundation was founded by visionary health care executive Richard Merkin, MD.

Richard Merkin, MD is the founder and CEO of Heritage Provider Network, Inc. (HPN). HPN is one of the largest physician founded and physician owned managed care organizations in the country dedicated to value-based healthcare delivery improvements. HPN develops and manages coordinated, patient-doctor centric, integrated health care systems that offer some of the strongest solutions for the future of health, care, and cost in the United States. HPN and its affiliates operate in New York, California, and Arizona, providing high-quality, cost-effective healthcare with over one million patient members. HPN is dedicated to quality, affordable health care, and putting patients' wellness first.

About Broad Institute of MIT and Harvard
Broad Institute was launched in 2004 to empower this generation of scientists to transform medicine. The Broad Institute seeks to describe the molecular components of life and their connections; discover the molecular basis of major human diseases; develop approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods, and data to the entire scientific community.

Founded by MIT, Harvard, Harvard-affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff, and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over 100 private and public institutions in more than 40 countries worldwide.

SOURCE Broad Institute of MIT and Harvard